| Literature DB >> 29431732 |
Yuying Liu1,2, Jiadi Lv1, Jinyan Liu1, Xiaoyu Liang1, Xun Jin1, Jing Xie1, Le Zhang1, Degao Chen1, Roland Fiskesund1,3,4, Ke Tang5, Jingwei Ma5, Huafeng Zhang5, Wenqian Dong1, Siqi Mo1, Tianzhen Zhang1, Feiran Cheng1, Yabo Zhou1, Qingzhu Jia6, Bo Zhu6, Yan Kong7, Jun Guo7, Haizeng Zhang8, Zhuo-Wei Hu9, Xuetao Cao1, F Xiao-Feng Qin10, Bo Huang1,2,5.
Abstract
Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell-intrinsic signaling pathways for entering into dormancy. Here, we show that IFN-β treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27-dependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-β signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-β correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-β provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities.Entities:
Keywords: Cancer; Immunology; Melanoma; Signal transduction; Stem cells
Mesh:
Substances:
Year: 2018 PMID: 29431732 PMCID: PMC5824876 DOI: 10.1172/JCI96329
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808